Your Source for Venture Capital and Private Equity Financings

Allay Therapeutics Completes $60M Series C

2021-09-16
MENLO PARK, CA, Allay Therapeutics, a clinical-stage biotechnology company, announced the completion of its oversubscribed $60M Series C financing.
Allay Therapeutics, a clinical-stage biotechnology company pioneering ultra-sustained analgesic products to transform post-surgical pain management and recuperation, announced the completion of its oversubscribed $60M Series C financing, led by Arboretum Ventures.

Participating in the round were NEA, Temasek, Pavilion Capital, Brandon Capital Partners, Vertex Growth, Vertex Ventures HC, and WTT Investment Ltd.
(c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000 startups and 5,000 VC investors


Featured Reading